Skip to main content

Table 2 Mortality analysis using Bayes statistics

From: Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study

Variable

N (%)

IC 95% Bayes

Deaths

Yes

5 (31.3)

(15.5; 58.6)

 

No

10 (62.5)

(41.0; 84.7)

 

Unknown

1 (6.2)

 

Causes of death

Hepatic breast carcinoma metastasis

1 (20.0)

(4.40; 64.5)

 

Respiratory infection

2 (40.0)

(12.1; 77.6)

 

Tumor progression

2 (40.0)

(12.1; 77.6)

Survival from the beginning of treatment

Mean

42.3 ± 6.6

(29.35; 55,21)

 

Median

56.5 ± 29.4

(0.00; 114.2)